Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates Apatinib treatment efficacy in gastric cancer.

A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression. Front Immunol (2017) 0.75

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16

Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52

The biology of VEGF and its receptors. Nat Med (2003) 32.13

Angiogenesis in cancer and other diseases. Nature (2000) 28.28

What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41

Vascular endothelial growth factor (VEGF) and its receptors. FASEB J (1999) 10.09

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res (2003) 9.92

Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol (2009) 5.56

VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene (1999) 2.66

Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell (2010) 2.64

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther (2006) 1.69

Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist (2000) 1.61

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci (2011) 1.53

Validation of the seventh edition of the American Joint Committee on Cancer TNM staging system for gastric cancer. Cancer (2011) 1.23

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer (2014) 1.22

VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist (2005) 1.13

VEGFR2 translocates to the nucleus to regulate its own transcription. PLoS One (2011) 1.12

Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene (2010) 1.08

VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther (2003) 1.07

Vascular endothelial growth factor a inhibition in gastric cancer. Gastric Cancer (2014) 1.07

Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. Drugs Today (Barc) (2015) 0.99

Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer. BMC Cancer (2014) 0.99

The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. Neoplasia (2012) 0.99

Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. Hepatology (2014) 0.97

Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway. Gastroenterology (2013) 0.93

Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer. Onco Targets Ther (2015) 0.89

Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade. Exp Mol Med (2013) 0.84

Ramucirumab: A Review in Advanced Gastric Cancer. BioDrugs (2015) 0.78